The Claim
In overweight or obese adults with type 2 diabetes, 14 weeks of liraglutide treatment is associated with a reduction in insulin resistance as measured by HOMA-IR (from 8.4 to 4.6 mol·mIU/L²) and an increase in insulin secretion as measured by HOMA-B (from 48.2 to 87.6 μIU/mmol), indicating improved pancreatic beta-cell function and insulin sensitivity.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In overweight or obese adults with type 2 diabetes, 14 weeks of liraglutide treatment is associated with lower insulin resistance and higher insulin secretion, reflecting improved pancreatic beta-cell function and insulin sensitivity.
See the scientific wording
In overweight or obese adults with type 2 diabetes, 14 weeks of liraglutide treatment is associated with a reduction in insulin resistance as measured by HOMA-IR (from 8.4 to 4.6 mol·mIU/L²) and an increase in insulin secretion as measured by HOMA-B (from 48.2 to 87.6 μIU/mmol), suggesting improved pancreatic beta-cell function and insulin sensitivity.
Liraglutide binds to receptors on the pancreas and liver, causing the pancreas to release more insulin and the liver to stop making too much glucose. This lowers blood sugar and reduces the body's resistance to insulin.
What the research says
1 studyIn people with type 2 diabetes who are overweight, taking liraglutide for 14 weeks helped their bodies use insulin better and made their pancreas produce more insulin, which is exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.